Randomized trials to optimize treatment of multidrug-resistant tuberculosis
Name:
Mitnick_MDRTBtrials_paper3_PLo ...
Size:
108.5Kb
Format:
PDF
Description:
Main article
Affiliation
Harvard Medical School, Boston, MA, USA; Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA, USA; Treatment Action Group, New York, NY, USA; Food and Drug Administration, Rockville, MD, USA; Denver Public Health and University of Colorado Health Sciences Center, Denver, CO, USAIssue Date
2007-11-06Submitted date
2008-06-13
Metadata
Show full item recordJournal
PLoS MedicinePubMed ID
17988168Type
ArticleLanguage
enISSN
1549-1676ae974a485f413a2113503eed53cd6c53
10.1371/journal.pmed.0040292
Scopus Count
Collections
Related articles
- State of the Art series on drug-resistant tuberculosis: it's time to protect fluoroquinolones.
- Authors: Chiang CY
- Issue date: 2009 Nov
- Multidrug-resistant tuberculosis (TB) resistant to fluoroquinolones and streptomycin but susceptible to second-line injection therapy has a better prognosis than extensively drug-resistant TB.
- Authors: Chan ED, Strand MJ, Iseman MD
- Issue date: 2009 Mar 1
- Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results.
- Authors: Migliori GB, Lange C, Girardi E, Centis R, Besozzi G, Kliiman K, Ortmann J, Matteelli A, Spanevello A, Cirillo DM, SMIRA/TBNET Study Group.
- Issue date: 2008 Mar 15
- Mechanisms of drug resistance in Mycobacterium tuberculosis.
- Authors: Zhang Y, Yew WW
- Issue date: 2009 Nov
- Trench warfare in a battle with TB.
- Authors: Marshall E
- Issue date: 2008 Jul 18